Jonathan Hoggatt

Jonathan Hoggatt


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Cell
Verified
Journal Article
Closed access
JHJonathan Hoggatt
Jonathan Hoggatt
PSPratibha Singh
Pratibha Singh
TTTiffany A. Tate
Tiffany A. Tate
BCBin-Kuan Chou
Bin-Kuan Chou
SDShruti R. Datari
Shruti R. Datari
LPLouis M. Pelus
Louis M. Pelus

1 February 2016 in Experimental Hematology
Verified
Journal Article
Closed access
JHJonathan Hoggatt
Jonathan Hoggatt
AHAmber F. Hoggatt
Amber F. Hoggatt
TTTiffany A. Tate
Tiffany A. Tate
JFJeffrey Fortman
Jeffrey Fortman
LPLouis M. Pelus
Louis M. Pelus

1 July 2016 in Cell
Verified
Journal Article
Closed access
JHJonathan Hoggatt
Jonathan Hoggatt

23 October 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPratibha Singh
Pratibha Singh
JHJonathan Hoggatt
Jonathan Hoggatt
MKMalgorzata M. Kamocka
Malgorzata M. Kamocka
KMKhalid S. Mohammad
Khalid S. Mohammad
MSMary R. Saunders
Mary R. Saunders
LPLouis M. Pelus
Louis M. Pelus
Endothelial cells (ECs) are components of the hematopoietic microenvironment and regulate hematopoietic stem and progenitor cell (HSPC) homeostasis. Cytokine treatments that cause HSPC trafficking to peripheral blood are associated with an increase in dipeptidylpeptidase 4/CD26 (DPP4/CD26), an enzyme that truncates the neurotransmitter neuropeptide Y (NPY). Here, we show that enzymatically altered NPY signaling in ECs caused reduced VE-cadherin and CD31 expression along EC junctions, resulting in increased vascular permeability and HSPC egress. Moreover, selective NPY2 and NPY5 receptor antagonists restored vascular integrity and limited HSPC mobilization, demonstrating that the enzymatically controlled vascular gateway specifically opens by cleavage of NPY by CD26 signaling via NPY2 and NPY5 receptors. Mice lacking CD26 or NPY exhibited impaired HSPC trafficking that was restored by treatment with truncated NPY. Thus, our results point to ECs as gatekeepers of HSPC trafficking and identify a CD26-mediated NPY axis that has potential as a pharmacologic target to regulate hematopoietic trafficking in homeostatic and stress conditions.

1 December 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
JHJonathan Hoggatt
Jonathan Hoggatt
JSJennifer Speth
Jennifer Speth
LPLouis M. Pelus
Louis M. Pelus
Hematopoietic stem cell transplantation is the only curative option for a number of malignant and nonmalignant diseases. As the use of hematopoietic transplant has expanded, so too has the source of stem and progenitor cells. The predominate source of stem and progenitors today, particularly in settings of autologous transplantation, is mobilized peripheral blood. This review will highlight the historical advances which led to the widespread use of peripheral blood stem cells for transplantation, with a look toward future enhancements to mobilization strategies. Stem Cells 2013;31:2599–2606

18 October 2021 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
JMJuan Bautista Menendez-Gonzalez
Juan Bautista Menendez-Gonzalez
JHJonathan Hoggatt
Jonathan Hoggatt